Ignite Creation Date:
2024-05-06 @ 10:23 AM
Last Modification Date:
2024-10-26 @ 12:29 PM
Study NCT ID:
NCT03249064
Status:
COMPLETED
Last Update Posted:
2017-08-22
First Post:
2017-08-10
Brief Title:
Response to Tregs in Innate Immunity Receptor LRP1 CD91 and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo
Sponsor:
Fundació Institut de Recerca de lHospital de la Santa Creu i Sant Pau
Organization:
Fundació Institut de Recerca de lHospital de la Santa Creu i Sant Pau
Study Overview
Official Title:
Response to Tregs in Innate Immunity Receptor LRP1 CD91 and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to evaluate some differences in the immune system between patients with vitiligo and patients without the disease
These differences will be evaluated by the extraction of peripheral blood that will be analyzed before the treatment and after the treatment that in the habitual way and at the discretion of the responsible dermatologist
Patients agreeing to participate in the study will be subjected to extraction of two tubes 20 ml of peripheral blood baseline and after 12 weeks - 5 days of treatment
Therefore neither treatment nor follow-up visits will be modified by participation but will be the same whether or not participate in the study
In the case of controls two peripheral blood tubes 20ml will be removed in a single participation
Patients with vitiligo will also be asked to complete questionnaires to measure stress depression and perception of disease PSS-10 Skindex-29 HADS Likert before and after 12 weeks - 5 days of therapeutic intervention
This study will include 20 patients with active non-segmental vitiligo and 10 controls without the disease The duration of participation in this study will be 12 weeks - 5 days for patients with vitiligo and a single participation extraction of 20 ml of peripheral venous blood for the controls
These differences will be evaluated by the extraction of peripheral blood that will be analyzed before the treatment and after the treatment that in the habitual way and at the discretion of the responsible dermatologist
Patients agreeing to participate in the study will be subjected to extraction of two tubes 20 ml of peripheral blood baseline and after 12 weeks - 5 days of treatment
Therefore neither treatment nor follow-up visits will be modified by participation but will be the same whether or not participate in the study
In the case of controls two peripheral blood tubes 20ml will be removed in a single participation
Patients with vitiligo will also be asked to complete questionnaires to measure stress depression and perception of disease PSS-10 Skindex-29 HADS Likert before and after 12 weeks - 5 days of therapeutic intervention
This study will include 20 patients with active non-segmental vitiligo and 10 controls without the disease The duration of participation in this study will be 12 weeks - 5 days for patients with vitiligo and a single participation extraction of 20 ml of peripheral venous blood for the controls
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None